•  
  •  
 

Abstract

Introduction. Chemotherapy is one of therapy choices for the advanced Non-Small Cell Lung Cancer (NSCLC). The success in therapy is measured with the 1-year survival, 2-year survival and the Progression Free Survival (PFS). The success is influenced by many factors: resistant to the citostatic, dosage, administer intensity, chemotherapy regiment, type histology, stage, performance status, comorbidity and social economic. In Indonesia, funding and chemotherapy regiment become the challenge for the success of therapy. Methods. The study used the Retrospective Cohort study with survival analysis. The Patients included in this study were the advanced NSC Lung Cancer (At least Stadium IIIa) who came to RSKD and RSCM during Jan 2006 – December 2010 for their first chemotherapy until finished the cycle (6 times) and had monitored for 2 years. Data was analyzed using cox regression analysis SPSS 16.0, and featured on the Kaplan Meier Curve. Results. Fifty five patients used EC and the other 55 patients used DC. There’s difference on survival where 1 year survival EC is 30,9% and DC is 47,3%, with p 0.030. Two year survival CE is 0% and for DC is 5.5%, with p 0.003. Also with the Median time survival between EC for 27 weeks and DC for 38 weeks with p < 0.016. Compared to DC, EC chemotherapy can increase the death risk by HR 1,684 (CI 95% 1,010-2,810), twenty four weeks PFS with EC is 54.5%, DC is 32.7% with p= 0.022. Conclusions. The survival with cisplatin-docexatel is better compared to cisplatin-etoposide, this applies to PFS as well.

References

1. Jemal A, Siegel R, Xu J. Ward E. Cancer statistics 2010. CA Cancer J Clin. 2010; 60(5):277-300. 2. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2007 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2010. p.146-53. 3. Tjindarbumi D, Mangunkusumo R. Cancer in Indonesia, present and future. Jpn J Clin Oncol. 2002;32(Suppl):S17-21. 4. Rekam Medis Rumah Sakit Kanker Dharmais. Jumlah kanker pasien rawat jalan (kasus baru) periode 2002-2007. Perjan Rumah Sakit Kanker Dharmais; 2008. (tidak dipublikasikan) 5. Noorwati. Data Epidemiologi Kanker Paru di Rumah Sakit Dharmais Periode 2005-2007. The third annual national cancer symposium: evidence based to practice; 2008 Mar 5-7; Jakarta. 6. Souhami RL, Tannock I, Hohenberger P, Horiot JC. Oxford Textbook of Oncology. Chem Carcinogen. 2002;2(2):21-34. 7. Molina JR, Ping Yang. Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clin Proc. 2008;83(5):584-94. 8. Paul A, Jr. Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Who, What, When, Why? J Clin Oncol. 2002;20:23-33. 9. Elisna S, Nina M, Achmad H. Efikasi dan Toksisitas Rejimen cisplatietoposide untuk Kemoterapi Kanker Paru Jenis Karsinoma Sel Kecil Stage Lanjut. J Respir Indo. 2012;32(1):25-35. 10. Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES, Thibodeau S, Jett J, Deschamps C. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005;128(1):452–62. 11. Lee NS, Hee-Sook, Jong-Ho. Randomized Multicenter Phase II Trial of Docetaxel Plus Cisplatin versus Etoposide Plus Cisplatin as The First Line Therapy for Patients with Advanced Non-small cell lung cancer. Cancer Res Treat. 2005;37(6):332-8. 12. Blanco JA, Toste IS, Alvarez RF, Cuadrado GR, Gonzalvez AM, Martín IJ. Age, comorbidity, treatment decision and prognosis in lung cancer. Age Ageing. 2008;37(6):715-8. 13. Dubey S dan Powell CA. Update in Lung Cancer 2008. Am J Respir Crit Care Med. 2009;179(10):860–8. 14. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Smoking and lung cancer survival: the role of comorbidity and treatment. Chest. 2004;125(1):27-37. 15. Yano T, Haro A, Shikada Y, Maruyama R, Maehara Y. Non-small cell lung cancer in never smokers as a representative 'nonsmokingassociated lung cancer': epidemiology and clinical features. Int J Clin Oncol. 2011;16(4):287-93. 16. Ebbert JO, Yang P, Vachon CM, et al. Lung cancer risk reduction after smo king cessation:observations from a prospective cohort of women. J Clin Oncol. 2003;21(5):921-26. 17. Molina JR et al. Non-small cell lung cancer: Epidemiology, Risk Factors, Treatment and Survivorship. Mayo Clin Proc. 2008;83(5):584-94. 18. Edgardo S, Belisario A. How Important is Histology in Treatment Selection for Non Small Cell Lung Cancer patients. Cancer Ther. 2009;7:324-31. 19. Sun Z, Aubry MC, Deschamps C, et al. Histologic grade is and independent pro gnostic factor for survival in non-small cell lung cancer: an analysis of 5018 hos pital-and 712 populationbased cases. J Thorac Cardiovase Surg. 2006;131(5):1014-20. 20. Tammemagi CM, Christine Neslund- Dudas, Michael Simoff, Impact of comorbidity on lung cancer survival. Int J Cancer. 2002;103(6):792–802. 21. Bonomi P, Fairclough D. Comprasion of survival and quality of life in advanced non-small lung cancer patients treated with two dose of paclitaxel combined with cisplatin versus otoposide and cisplatin: Results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000;18(3):623-31. 22. Tambunan T, Soetomenggolo TS, Passat J, Agusman IS. Studi Kohort. Dalam: Sastroasmoro S, Ismael S, editor. Dasar-Dasar Metodologi Penelitian Klinis Edisi 2. Jakarta: Sagung Seto; 2002. hal.2128-42. 23. Schiller JH, Harrington D et al. Comparison of four chemotherapy regiment for advanced nonsmall cell lung cancer. N engl J Med. 2002;346(2):92-8. 24. Fuertes MA, Castillab J, Alonsoa C, Perez JM. Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptonic and necrotic pathways. Curr Med Chem. 2003;10(3):257-66.

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.